PRE VS SYRS Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price Targets
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price Targets

Performance

PRE
10/100

PRE returned -86.81% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

SYRS
10/100

SYRS returned -32.17% in the last 12 months. Based on SPY's performance of -11.19%, its performance is below average giving it a score of 10 of 100.

Technicals

PRE
36/100

PRE receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

SYRS
36/100

SYRS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Earnings

PRE
44/100

PRE has missed earnings 2 times in the last 20 quarters.

SYRS
10/100

SYRS has missed earnings 7 times in the last 20 quarters.

Profit

PRE
13/100

Out of the last 10 quarters, PRE has had 2 profitable quarters and has increased their profits year over year on 1 of them.

SYRS
10/100

Out of the last 20 quarters, SYRS has had 0 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

PRE
55/100

PRE has had a higher than average amount of volatility over the last 12 months giving it a score of 54 of 100.

SYRS
45/100

SYRS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Analyst Price Targets

PRE

"Analyst Price Targets" not found for PRE

SYRS
75/100

7 analysts offer 12-month price targets for SYRS. Together, they have an average target of 30, the most optimistic target put SYRS at 30 within 12-months and the most pessimistic has SYRS at 30.

All score calculations are broken down here to help you make more informed investing decisions

Prenetics Global Limited Class A Ordinary Share Summary

Nasdaq / PRE
Healthcare
Medical - Diagnostics & Research
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

Syros Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / SYRS
Healthcare
Biotechnology
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.